Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATEC NASDAQ:LMNX NASDAQ:MDXG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATECAlphatec$8.24+0.2%$10.59$6.82▼$23.29$1.27B0.963.37 million shs2.02 million shsLMNXDefiance Daily Target 2X Long LMND ETF$13.52+12.5%$16.52$10.81▼$55.00$4.46M-10.8946,870 shs18,481 shsMDXGMiMedx Group$3.79+4.1%$3.82$3.03▼$7.99$564.52M1.461.29 million shs1.20 million shs7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATECAlphatec+1.61%+6.20%-25.95%-39.29%-36.91%LMNXDefiance Daily Target 2X Long LMND ETF-2.27%-5.64%-46.23%-42.47%-67.42%MDXGMiMedx Group+1.39%+2.82%+6.74%-30.27%-49.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATECAlphatec$8.24+0.2%$10.59$6.82▼$23.29$1.27B0.963.37 million shs2.02 million shsLMNXDefiance Daily Target 2X Long LMND ETF$13.52+12.5%$16.52$10.81▼$55.00$4.46M-10.8946,870 shs18,481 shsMDXGMiMedx Group$3.79+4.1%$3.82$3.03▼$7.99$564.52M1.461.29 million shs1.20 million shs7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATECAlphatec+1.61%+6.20%-25.95%-39.29%-36.91%LMNXDefiance Daily Target 2X Long LMND ETF-2.27%-5.64%-46.23%-42.47%-67.42%MDXGMiMedx Group+1.39%+2.82%+6.74%-30.27%-49.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATECAlphatec 2.75Moderate Buy$18.58125.53% UpsideLMNXDefiance Daily Target 2X Long LMND ETF 0.00N/AN/AN/AMDXGMiMedx Group 2.71Moderate Buy$8.50124.27% UpsideCurrent Analyst Ratings BreakdownLatest LMNX, ATEC, and MDXG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026MDXGMiMedx Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/7/2026ATECAlphatec BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$27.00 ➝ $24.005/7/2026ATECAlphatec Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$28.00 ➝ $14.005/7/2026ATECAlphatec HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.005/6/2026ATECAlphatec Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/6/2026ATECAlphatec Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.005/6/2026ATECAlphatec Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$25.00 ➝ $23.005/6/2026ATECAlphatec Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$25.00 ➝ $14.005/6/2026ATECAlphatec BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$27.00 ➝ $24.005/6/2026ATECAlphatec JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$24.00 ➝ $16.005/6/2026ATECAlphatec TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $11.00(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATECAlphatec$764.16M1.66N/AN/A($0.03) per share-274.67LMNXDefiance Daily Target 2X Long LMND ETF$437.66M0.01$0.41 per share32.98$11.13 per share1.21MDXGMiMedx Group$418.63M1.35$0.58 per share6.48$1.63 per share2.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATECAlphatec-$143.36M-$0.82N/A164.80N/A-15.93%-1,183.84%-15.83%7/30/2026 (Estimated)LMNXDefiance Daily Target 2X Long LMND ETF$15.17M$0.5126.5111.27N/A5.39%4.66%2.91%N/AMDXGMiMedx Group$48.58M$0.2018.9563.17N/A7.88%21.03%15.92%7/29/2026 (Estimated)Latest LMNX, ATEC, and MDXG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026ATECAlphatec-$0.01-$0.22-$0.21-$0.22$197.51 million$192.11 million4/29/2026Q1 2026MDXGMiMedx Group-$0.07-$0.05+$0.02-$0.07$65.80 million$58.99 million2/25/2026Q4 2025MDXGMiMedx Group$0.09$0.14+$0.05$0.10$106.78 million$118.10 million2/24/2026Q4 2025ATECAlphatec$0.04$0.06+$0.02-$0.14$212.67 million$212.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATECAlphatecN/AN/AN/AN/AN/ALMNXDefiance Daily Target 2X Long LMND ETF$0.403.07%N/A78.43%N/AMDXGMiMedx GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATECAlphatec40.351.901.12LMNXDefiance Daily Target 2X Long LMND ETF0.528.376.08MDXGMiMedx Group0.075.394.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATECAlphatec66.35%LMNXDefiance Daily Target 2X Long LMND ETF87.76%MDXGMiMedx Group79.15%Insider OwnershipCompanyInsider OwnershipATECAlphatec13.48%LMNXDefiance Daily Target 2X Long LMND ETF6.60%MDXGMiMedx Group2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATECAlphatec700153.79 million133.06 millionOptionableLMNXDefiance Daily Target 2X Long LMND ETF1,325330,000N/AOptionableMDXGMiMedx Group870148.95 million145.22 millionOptionableLMNX, ATEC, and MDXG HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, ...May 19 at 11:20 PM | caledonianrecord.comCINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXGMay 19 at 6:15 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXGMay 14, 2026 | prnewswire.comMiMedx Group (MDXG) price target decreased by 18.75% to 6.63May 14, 2026 | msn.comMiMedx Group, Inc (NASDAQ:MDXG) Receives $8.50 Average Price Target from BrokeragesMay 14, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXGMay 12, 2026 | globenewswire.comIs the Options Market Predicting a Spike in MiMedx Group Stock?May 11, 2026 | zacks.comMiMedx Group, Inc (NASDAQ:MDXG) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 9, 2026 | marketbeat.comMiMedx: The Hard Math Behind My Downgrade To HoldMay 9, 2026 | seekingalpha.comMIMEDX Announces Launch of G4Derm® PlusMay 8, 2026 | globenewswire.comSome May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) EarningsMay 7, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXGMay 7, 2026 | prnewswire.comHow Reimbursement Shifts Are Rewriting The MiMedx Group (MDXG) Investment NarrativeMay 5, 2026 | uk.finance.yahoo.comMiMedx Group, Inc. (NASDAQ:MDXG) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMay 3, 2026 | finance.yahoo.comMiMedx Group (MDXG) Launches CHORIOFIX Placental Allograft for Complex, Tunneling WoundsMay 2, 2026 | insidermonkey.comMiMedx Group (NASDAQ:MDXG) Stock Rating Lowered by Wall Street ZenMay 2, 2026 | marketbeat.comMiMedx Group (NASDAQ:MDXG) Stock Price Up 7% - Still a Buy?May 1, 2026 | marketbeat.comMiMedx Group (NASDAQ:MDXG) Price Target Lowered to $6.00 at Citizens JmpApril 30, 2026 | marketbeat.comMiMedx Group, Inc: MIMEDX Announces First Quarter 2026 Operating & Financial ResultsApril 30, 2026 | finanznachrichten.deMiMedx Group Inc (MDXG) Q1 2026 Earnings Call Highlights: Navigating Growth and ChallengesApril 30, 2026 | finance.yahoo.comMimedx expects $260M-$290M 2026 net sales amid $40M cost cuts and wound care reimbursement disruptionApril 30, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLMNX, ATEC, and MDXG Company DescriptionsAlphatec NASDAQ:ATEC$8.24 +0.02 (+0.24%) Closing price 04:00 PM EasternExtended Trading$8.17 -0.07 (-0.83%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.Defiance Daily Target 2X Long LMND ETF NASDAQ:LMNX$13.52 +1.50 (+12.48%) As of 03:57 PM EasternLuminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.MiMedx Group NASDAQ:MDXG$3.79 +0.15 (+4.12%) Closing price 04:00 PM EasternExtended Trading$3.71 -0.08 (-2.11%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
